Garattini, Livio; van de Vooren, Katelijne; Curto, … - In: Health Policy 119 (2015) 2, pp. 212-216
Trastuzumab (TR), a monoclonal antibody approved by EMA in 2000 and one of the first examples of “targeted therapy”, is indicated to treat human epidermal growth factor receptor 2 (HER2) positive breast cancer. TR, whose patent will expire in 2015 in Europe, has been judged positively for...